Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Alignment Healthcare Inc’s stock clocked out at $14.57, down -0.27% from its previous closing price of $14.61. In other words, the price has decreased by -$0.27 from its previous closing price. On the day, 1.18 million shares were traded. ALHC stock price reached its highest trading level at $14.66 during the session, while it also had its lowest trading level at $14.23.
Ratios:
To gain a deeper understanding of ALHC’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.91.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stephens on December 03, 2024, Upgraded its rating to Overweight and sets its target price to $17 from $13 previously.
BofA Securities Upgraded its Neutral to Buy on May 30, 2024, whereas the target price for the stock was revised from $7.75 to $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 21 ’25 when Kardes Hakan sold 10,500 shares for $14.99 per share. The transaction valued at 157,370 led to the insider holds 309,944 shares of the business.
HAKAN KARDES bought 25,000 shares of ALHC for $364,500 on Jan 21 ’25. On Jan 15 ’25, another insider, Maroney Dawn Christine, who serves as the President of the company, sold 30,000 shares for $13.61 each. As a result, the insider received 408,384 and left with 1,606,097 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALHC now has a Market Capitalization of 2793010688 and an Enterprise Value of 2633303040. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.13 while its Price-to-Book (P/B) ratio in mrq is 24.37. Its current Enterprise Value per Revenue stands at 1.067 whereas that against EBITDA is -28.109.
Stock Price History:
The Beta on a monthly basis for ALHC is 1.51, which has changed by 1.087143 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, ALHC has reached a high of $15.03, while it has fallen to a 52-week low of $4.46. The 50-Day Moving Average of the stock is 19.86%, while the 200-Day Moving Average is calculated to be 51.38%.
Shares Statistics:
It appears that ALHC traded 1.91M shares on average per day over the past three months and 2108290 shares per day over the past ten days. A total of 191.60M shares are outstanding, with a floating share count of 92.27M. Insiders hold about 51.88% of the company’s shares, while institutions hold 42.58% stake in the company. Shares short for ALHC as of 1735603200 were 9577322 with a Short Ratio of 5.01, compared to 1732838400 on 11110055. Therefore, it implies a Short% of Shares Outstanding of 9577322 and a Short% of Float of 7.8.
Earnings Estimates
The current assessment of Alignment Healthcare Inc (ALHC) involves the perspectives of 5.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.28 and -$0.29 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.09, with 5.0 analysts recommending between -$0.02 and -$0.15.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $675.61M. It ranges from a high estimate of $689.4M to a low estimate of $668.2M. As of the current estimate, Alignment Healthcare Inc’s year-ago sales were $465.39MFor the next quarter, 10 analysts are estimating revenue of $854.69M. There is a high estimate of $927.88M for the next quarter, whereas the lowest estimate is $812.95M.
A total of 11 analysts have provided revenue estimates for ALHC’s current fiscal year. The highest revenue estimate was $2.69B, while the lowest revenue estimate was $2.67B, resulting in an average revenue estimate of $2.68B. In the same quarter a year ago, actual revenue was $1.82BBased on 11 analysts’ estimates, the company’s revenue will be $3.48B in the next fiscal year. The high estimate is $3.7B and the low estimate is $3.37B.
